The incidence of wet-AMD and diabetic eye diseases are increasing globally. Current treatment options place a significant treatment burden on patients, but a flourishing pipeline of innovative therapeutic options with high efficacy and lower invasiveness is disrupting the status quo.The Retinal Vascular Disease Drug Development Summit will unite the industry leaders at the forefront of developing and delivering these innovative treatments, providing you with an unparalleled quality of technical insights specifically enabling you to progress your retinal vascular disease pipeline more quickly and effectively to get these innovative therapeutics to market.